摘要
人类趋化因子系统由19种7次跨膜螺旋(7TM)的受体和45种内源性趋化因子组成,他们经常以一种混合方式相互作用。由于趋化因子系统以白细胞游出为主要功能,所以它在免疫稳态和免疫监视中起到主要作用。趋化因子是分子量为8-12 kDa的多肽类家族其二级结构具有弹性的N端和核心区组成并通常由保守的二硫键稳定结构。他们主要与他们同源的7TM受体细胞外区域相互作用。亲和力与相互作用贡献的活性归因于不同的区域,并以两个步骤进行。在此,第一个结合步骤涉及对趋化因子和受体域的了解,并且对第二个激活步骤进行了综述。至少由两个步骤组成的机制似乎是一致的;然而,如最近提出的其它7TM受体一样,可能会产生许多中间反应,从而导致多步骤的机制过程。总的来说,趋化因子受体的N端是结合所有趋化因子的关键。在受体激活过程中,两个主要的趋化因子亚组之间会出现许多不同,如CC趋化因子主要作用或者依赖于横跨膜的受体残基,而CXC趋化因子使用更外层的残基。而且,相同受体的不同趋化因子经常在不同的位点结合,揭示了许多正性结合位点的存在,因此增加了另一水平的复杂性。这引起了小分子“药物样”探针依赖型配体的产生,依赖于趋化因子反应的这种配体可能会与某些变构体结合,或与以相同受体为靶点的其它趋化因子正性结合,从而引出了探针依赖型药理学。
关键词: 7TM受体,趋化因子,G蛋白耦联受体(GPCR),配体受体相互作用,突变,正性结合位点,结构,两步机制。
Current Medicinal Chemistry
Title:Interaction of Chemokines with their Receptors - From Initial Chemokine Binding to Receptor Activating Steps
Volume: 21 Issue: 31
Author(s): Stefanie Thiele and Mette Marie Rosenkilde
Affiliation:
关键词: 7TM受体,趋化因子,G蛋白耦联受体(GPCR),配体受体相互作用,突变,正性结合位点,结构,两步机制。
摘要: The human chemokine system comprises 19 seven-transmembrane helix (7TM) receptors and 45 endogenous chemokines that often interact with each other in a promiscuous manner. Due to the chemokine system’s primary function in leukocyte migration, it has a central role in immune homeostasis and surveillance. Chemokines are a group of 8-12 kDa large peptides with a secondary structure consisting of a flexible N-terminus and a core-domain usually stabilized by two conserved disulfide bridges. They mainly interact with the extracellular domains of their cognate 7TM receptors. Affinityand activity-contributing interactions are attributed to different domains and known to occur in two steps. Here, knowledge on chemokine and receptor domains involved in the first binding-step and the second activation-step is reviewed. A mechanism comprising at least two steps seems consistent; however, several intermediate interactions possibly occur, resulting in a multi-step process, as recently proposed for other 7TM receptors. Overall, the N-terminus of chemokine receptors is pivotal for binding of all chemokines. During receptor activation, differences between the two major chemokine subgroups occur, as CC-chemokines mainly interact with or rely on transmembrane receptor residues, while CXC-chemokines use residues located further exterior. Moreover, different chemokines for the same receptor often bind at different sites, uncovering the existence of several orthosteric sites thereby adding another level of complexity. This gives rise to a probe-dependency of small molecule “drug-like” ligands, which, depending on the chemokine interaction, may bind allosteric for some, and orthosteric for other chemokines targeting the same receptor, thereby resulting in probedependent pharmacodynamics.
Export Options
About this article
Cite this article as:
Thiele Stefanie and Rosenkilde Marie Mette, Interaction of Chemokines with their Receptors - From Initial Chemokine Binding to Receptor Activating Steps, Current Medicinal Chemistry 2014; 21 (31) . https://dx.doi.org/10.2174/0929867321666140716093155
DOI https://dx.doi.org/10.2174/0929867321666140716093155 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Management of Hypertension in the Acute Phase of Stroke
Current Hypertension Reviews Subcutaneous Immunoglobulins: A Promising Alternative for Immunomodulation?
Current Pharmaceutical Design Evaluation of Gene and Cell-Based Therapies for Cardiac Regeneration
Current Stem Cell Research & Therapy Medication-Induced Nephrotoxicity in Older Patients
Current Drug Metabolism Therapeutic Effect of Ghrelin in the Course of Ischemia/Reperfusion-Induced Acute Pancreatitis
Current Pharmaceutical Design Diabetes-induced Epigenetic Signature in Vascular Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets The Neuroprotective Role of Repetitive Transcranial Magnetic Stimulation (rTMS) for Neurodegenerative Diseases: A Short Review on Experimental Studies
Mini-Reviews in Medicinal Chemistry Role of Oxidative Stress in Renal Transplantation: Bases for an n-3 PUFA Strategy Against Delayed Graft Function
Current Medicinal Chemistry Aldose Reductase: A Multi-disease Target
Current Enzyme Inhibition Biotransformations of Prenylated Hop Flavonoids for Drug Discovery and Production
Current Drug Metabolism Common Therapeutic Strategies for Diabetic Retinopathy and Glaucoma
Current Drug Therapy Recent Advances in Health Promoting Effect of Dietary Polyphenols
Current Nutrition & Food Science Emerging Role for Antioxidant Therapy in Protection Against Diabetic Cardiac Complications: Experimental and Clinical Evidence for Utilization of Classic and New Antioxidants
Current Cardiology Reviews DNAzyme Delivery Approaches in Biological Settings
Current Medicinal Chemistry Mild Mitochondrial Uncoupling as a Therapeutic Strategy
Current Drug Targets Intravenous Antihypertensives within Cardiovascular-Based Continuity of Care
Current Vascular Pharmacology Editorial: [Hot Topic: Non-Analgesic Effects of Opioids]
Current Pharmaceutical Design Roles of miRNA in Cardiovascular Development and Dysfunction
Current Medicinal Chemistry Recent Updates on the Association Between Alzheimer’s Disease and Vascular Dementia
Medicinal Chemistry Cytochrome P450-Activated Prodrugs: Targeted Drug Delivery
Current Medicinal Chemistry